#sanofi — Public Fediverse posts

ADEL Nears IPO on Sanofi Deal, Eyes New Tech Transfer Within 1-2 Years

ADEL CEO Yoon Seung-yong explains the Alzheimer’s disease drug candidate “ADEL-Y01” at the company’s headquarters in Gangdong-gu, Seoul,…
#France #FR #Europe #EU #Sanofi #ADEL #ADEL-Y01 #Alzheimer'sdiseasetreatment #ApoE4antibody #blood-brainbarrierplatform #KOSDAQIPO #technologytransfer
https://www.europesays.com/france/53734/

Weil Advises Sanofi in its $2.2 Billion Acquisition of Dynavax

Weil is advising Sanofi in its agreement to acquire Dynavax Technologies Corporation, a publicly traded vacc…
#France #FR #Europe #EU #Sanofi #Antitrust #AntitrustCartelandInvestigations #AntitrustLitigation #capitalmarkets #D.C. #ExecutiveCompensation&Benefits #Mergers&Acquisitions #NewYork #Privacy&Cybersecurity #realestate #RegulatoryTransactions #Tax #Technology&IPTransactions #Washington
https://www.europesays.com/france/53656/

Sanofi gets FDA approval for Sarclisa on-body injector | SNY SEC Filing

“The introduction of Sarclisa Escena with the innovative CirCLIQ on-body injector represents a significant advancement in multiple myeloma…
#France #FR #Europe #EU #Sanofi #CirCLIQ #EnableInjections #enFuse #FDAapproval #multiplemyeloma #on-bodyinjector #phase3IRAKLIA #SarclisaEscena #SNY
https://www.europesays.com/france/52785/

Sanofi joins the mRNA vaccine patent wars

Why it matters: The lawsuits give Sanofi another route to extract value from the mRNA technology it acquired…
#France #FR #Europe #EU #Sanofi #intellectualproperty
https://www.europesays.com/france/52196/

Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following…
#France #FR #Europe #EU #Sanofi #Announces #Appointment #as #at #board #following #Fontoura #from #global #has #head #his #Its #Lakefront #of #Paulo #R&D #Resigned
https://www.europesays.com/france/50876/

https://www.europesays.com/es/654908/ “En enfermedades raras, la posibilidad de intervenir a nivel genético es prometedora” #A1 #EnfermedadesRaras #ES #España #Health #Laboratorios #Salud #Sanofi #Spain

Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
#France #FR #Europe #EU #Sanofi #antitrustinvestigation #fluvaccine #SarclisaEscena #SimplyWallSt #TheEuropeanCommission
https://www.europesays.com/france/49810/

Sanofi (ENXTPA:SAN) Wins FDA Nod For Sarclisa Escena As EU Opens Antitrust Probe

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
#Europe #EU #antitrustinvestigation #EuropeanUnion #fluvaccine #Sanofi #SarclisaEscena #SimplyWallSt #TheEuropeanCommission
https://www.europesays.com/europe/91647/

ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

LYON, France, July 03, 2026–(BUSINESS WIRE)–Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical…
#France #FR #Europe #EU #Sanofi #Adocia #EuronextParis #exclusivityagreement #globalrights #OlivierSoula #partnershipagreement #researchanddevelopment #type1diabetes
https://www.europesays.com/france/48313/

Sanofi posts positive Nexviazyme phase 3 IOPD data | SNY SEC Filing

About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling…
#France #FR #Europe #EU #Sanofi #Baby-COMET #biopharma #enzymereplacementtherapy #infantile-onsetPompe #labelextension #Nexviazyme #phase3trial #Pompedisease #SNY
https://www.europesays.com/france/47935/

ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

LYON, France, July 03, 2026–(BUSINESS WIRE)–Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical…
#France #FR #Europe #EU #Sanofi #Adocia #EuronextParis #exclusivityagreement #globalrights #OlivierSoula #partnershipagreement #researchanddevelopment #type1diabetes
https://www.europesays.com/france/45649/

Monroe County vaccine plant gets $10.6 million boost

THE LANCASTER COUNTY SOLID WASTE MANAGEMENT AUTHORITY SAYING THEY WILL BE PART OF THE PROCE…
#France #FR #Europe #EU #Sanofi #$10.6million #Carbonemissions #Commonwealth #dehydrators #eggwaste #fertilizedeggs #fluvaccine #JoshShapiro #LifeSciences #manufacturingplant #monroecounty #naturalgas #paddledryer #Pennsylvania #Shapiroadministration #Swiftwater #vaccinedoses #vaccinemanufacturing #vaccineplant
https://www.europesays.com/france/44496/

Sanofi (ENXTPA:SAN) Faces EU Antitrust Probe As Nexviazyme Trial Delivers Positive Data

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
#France #FR #Europe #EU #Sanofi #antitrustinvestigation #EuropeanCommission #EuropeanEconomicArea #fluvaccine #Pompedisease #rarediseases #SimplyWallSt
https://www.europesays.com/france/43941/

Sanofi (ENXTPA:SAN) Faces EU Antitrust Probe As Nexviazyme Trial Delivers Positive Data

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
#Europe #EU #antitrustinvestigation #EuropeanCommission #europeaneconomicarea #EuropeanUnion #fluvaccine #Pompedisease #rarediseases #Sanofi #SimplyWallSt
https://www.europesays.com/europe/82995/

Sanofi Pasteur receives $10.6M RISE PA grant

Listen to this article State officials visited the Sanofi Pasteur‘s Swiftwater vaccine manufacturing facility on Friday to announce…
#France #FR #Europe #EU #Sanofi #influenzavaccine #monroecounty #RISEPAgrant #SanofiPasteur #Swiftwater #vaccinemanufacturing
https://www.europesays.com/france/43582/

EU Commission launches antitrust investigation into Sanofi

The logo of the French drug manufacturer Sanofi, taken during a general meeting of the pharmaceutical company. (is…
#France #FR #Europe #EU #Sanofi #antitrustinvestigation #antitrustlaw #drugmanufacturer #eucommission #EuropeanUnion #fluvaccine
https://www.europesays.com/france/43083/

EU Commission launches antitrust investigation into Sanofi

The logo of the French drug manufacturer Sanofi, taken during a general meeting of the pharmaceutical company. (is…
#Europe #EU #EuropeanCommission #antitrustinvestigation #AntitrustLaw #drugmanufacturer #EUCommission #EuropeanUnion #fluvaccine #Sanofi
https://www.europesays.com/europe/81560/

Sanofi wins key EU, Japan drug approvals and new R&D head | SNY SEC Filing

About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling…
#France #FR #Europe #EU #Sanofi #Cenrifki #drugapprovals #Form6-K #immunethrombocytopenia #multiplemyeloma #multiplesclerosis #PauloFontoura #Sarclisa #SNY #Wayrilz
https://www.europesays.com/france/40606/

Sanofi (ENXTPA:SAN) Wins Two Drug Approvals In Japan And The EU

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide. Sanofi secured approval in Japan for Wayrilz (rilzabrutinib) to treat chronic immune thrombocytopenia. Cenrifki (tolebr…
#Japan #JP #JapanNews #immunethrombocytopenia #marketedproducts #news #Sanofi
https://www.alojapan.com/1502797/sanofi-enxtpasan-wins-two-drug-approvals-in-japan-and-the-eu/

https://www.alojapan.com/1502797/sanofi-enxtpasan-wins-two-drug-approvals-in-japan-and-the-eu/ Sanofi (ENXTPA:SAN) Wins Two Drug Approvals In Japan And The EU #ImmuneThrombocytopenia #Japan #JapanNews #MarketedProducts #news #Sanofi Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide. Sanofi secured approval in Japan for Wayrilz (rilzabrutinib) to treat chronic immune thrombocytopenia. Cenrifki (tolebrutinib) received EU approval for progressive mu

Backed by Sanofi and Roche, Orano Med chases radiopharma leadership

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily…
#France #FR #Europe #EU #Sanofi #FrédéricDesdouits #Orano #OranoMed #radioactiveisotope
https://www.europesays.com/france/40174/

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disabil…
#France #FR #Europe #EU #Sanofi #approved #as #Cenrifki #disability-targeting #first #for #in #Medicine #multiple #press #progressive #relapses #release #Sanofi’s #sclerosis #secondary #the #tolebrutinib #Without
https://www.europesays.com/france/39708/

Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
#France #FR #Europe #EU #Sanofi #ChiefMedicalOfficer #experimentaldrug #Fontoura #HoumanAshrafian #Merck #Mondaymorning #PrometheusBiosciences #researchanddevelopment #ventureinvestor
https://www.europesays.com/france/39421/

Alteogen Names Sanofi as First Licensee of ALT-B4 Technology

A view of Alteogen’s headquarters. Photo courtesy of Alteogen Alteogen (196170.KQ) disclosed Tuesday that global pharmaceutical company Sanofi…
#France #FR #Europe #EU #Sanofi #ALT-B4 #Alteogen #autoimmunediseasetreatment #Dupixent #pharmaceuticallicensing #subcutaneousformulation #technologytransfer
https://www.europesays.com/france/37617/

Sanofi asks out of CNPV fast-track program for Tzield expansion

Since it was established nearly a year ago by the FDA, the Commissioner’s National Priority Voucher (CNPV) program…
#France #FR #Europe #EU #Sanofi #Commissioner’sNationalPriorityVoucher(CNPV) #FDA #FDApriorityreview #FiercePharmaHomepage #pharma #type1diabetes
https://www.europesays.com/france/37314/

After a 2-month delay, Sanofi gains FDA expansion of Tzield

After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in…
#France #FR #Europe #EU #Sanofi #Commissioner’sNationalPriorityVoucher(CNPV) #FDA #FiercePharmaHomepage #pharma #type1diabetes
https://www.europesays.com/france/37293/

Alteogen Names Sanofi as First Licensee of ALT-B4 Technology

A view of Alteogen’s headquarters. Photo courtesy of Alteogen Alteogen (196170.KQ) disclosed Tuesday that global pharmaceutical company Sanofi…
#France #FR #Europe #EU #Sanofi #ALT-B4 #Alteogen #autoimmunediseasetreatment #Dupixent #pharmaceuticallicensing #subcutaneousformulation #technologytransfer
https://www.europesays.com/france/37285/

Astellas appoints new top strategist—Chutes & Ladders

Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the…
#France #FR #Europe #EU #Sanofi #AstellasPharma #Biotech #ChutesandLadders #ConvergentTherapeutics #EvaxionBiotech #FierceBiotechHomepage #Immunic #Nuevocor #Unither
https://www.europesays.com/france/35136/

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed wi…
#France #FR #Europe #EU #Sanofi #1 #3 #approved #as #diabetes #diagnosed #disease-modifying #first #for #in #patients #press #recently #release #Sanofi’s #stage #the #therapy #type #Tzield #Us #with
https://www.europesays.com/france/35008/

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi Xw-V46t3ppW-m0Vg8loC2rrmMOcGpekzm0rXj6c0nkCxRad_A_U=” target=”_blank”…
#France #FR #Europe #EU #Sanofi #kymera-therapeutics-inc #kymr #life-science-investing #nasdaq-kymr
https://www.europesays.com/france/33775/

Sanofi, Parabilis, AWS, Kendall Square: Readout Newsletter

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
#France #FR #Europe #EU #Sanofi #biotechnology #drugdevelopment #Drugprices #research
https://www.europesays.com/france/33725/

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milesto…
#France #FR #Europe #EU #Sanofi #1 #Achievement #and #Announces #collaboration #Degrader #Dosed #first #in #IRAK4 #KT-485 #Kymera #Milestone #of #Oral #Participant #Phase #Therapeutics #trial #under
https://www.europesays.com/france/33037/

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

Sanofi SNY announced that the European Commission (EC) has approved the subcutaneous (under the skin or SC) formulation…
#France #FR #Europe #EU #Sanofi #futures #indexmarketquote #indexmarketquotes #indexmarketsymbol #indexmarketsymbols #indices #Sanofi-AventisS.A.ADR #SNY #TheGlobeandMail
https://www.europesays.com/france/32739/

Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa…
#France #FR #Europe #EU #Sanofi #administered #an #anticancer #approved #as #first #in #injector #on-body #press #release #Sanofi’s #Sarclisa #subcutaneous #the #treatment #via
https://www.europesays.com/france/32282/

Press Release: Sanofi’s lunsekimig met primary and key

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES phase…
#France #FR #Europe #EU #Sanofi #asthma #asthme #clinicalresearch #Cytokines #essaiscliniques #health #inflammation #maladiesrespiratoires #Nanobody #ParisStockExchange:SAN #Pharmaceuticals #respiratorydisease #SanofiWinthropIndustrie #Santé
https://www.europesays.com/france/30955/

Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth…
#France #FR #Europe #EU #Sanofi #futures #indexmarketquote #indexmarketquotes #indexmarketsymbol #indexmarketsymbols #indices #Sanofi-AventisS.A.ADR #SNY #TheGlobeandMail
https://www.europesays.com/france/30783/

Sanofi – Combined General Meeting of April 29, 2026

Sanofi Winthrop Industrie COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are…
#France #FR #Europe #EU #Sanofi #avisdeconvocation #GeneralMeeting #NoticeofMeeting #PalaisdesCongrès #PorteMaillot #preparatorydocuments #shareholders
https://www.europesays.com/france/30450/

GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth

GSK plc’s GSK Specialty Medicines business has become the company’s primary growth engine, accounting for more than 40%…
#EuropeSays #Britain #Europe #EU #GSK #futures #indexmarketquote #indexmarketquotes #indexmarketsymbol #indexmarketsymbols #indices #Sanofi-AventisS.A.ADR #SNY #TheGlobeandMail
https://www.europesays.com/britain/55434/

FDA grants priority review for Sanofi’s venglustat NDA

Sanofi has received a priority review from the US Food and Drug Administration (FDA) for its new drug…
#France #FR #Europe #EU #Sanofi #ERT #FoodandDrugAdministration #neurologicalsymptoms #priorityreview #type3Gaucherdisease
https://www.europesays.com/france/27428/

FDA grants priority review for Sanofi’s venglustat NDA

Sanofi has received a priority review from the US Food and Drug Administration (FDA) for its new drug…
#France #FR #Europe #EU #Sanofi #ERT #FoodandDrugAdministration #neurologicalsymptoms #priorityreview #type3Gaucherdisease
https://www.europesays.com/france/26946/

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi Winthrop Industrie Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease…
#France #FR #Europe #EU #Sanofi #bloodbrainbarrier #ERT #Fabrydisease #Gaucherdisease #neurologicalmanifestations #orphandesignation #pediatricpatients #potential
https://www.europesays.com/france/26133/

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi Winthrop Industrie Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease…
#France #FR #Europe #EU #Sanofi #bloodbrainbarrier #ERT #Fabrydisease #Gaucherdisease #neurologicalmanifestations #orphandesignation #pediatricpatients #potential
https://www.europesays.com/france/26078/

Sanofi is building its own AI ecosystem to give the French pharma giant an edge

In the early days of the generative artificial intelligence boom, Sanofi’s chief digital officer, Emmanuel Frenehard, wasn’t particularly…
#France #FR #Europe #EU #Sanofi #chiefinformationofficer(CIO) #chieftechnologyofficer(CTO) #CIOIntelligence #Fortune500 #PharmaceuticalIndustry
https://www.europesays.com/france/25707/

Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head

Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi, after the French vaccine specialist…
#France #FR #Europe #EU #Sanofi #Hudson #MerckKGaA #PaulHudson
https://www.europesays.com/france/24149/

Nanobody Tech: Multi-Targeting for Complex Disease Therapies

In late 19th century Germany, the rise of diphtheria and tetanus had researchers racing to find treatments. In…
#France #FR #Europe #EU #Sanofi #antibody #drugdiscovery #innovation #Nanobody
https://www.europesays.com/france/21812/

Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Sanofi Winthrop Industrie ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head,…
#France #FR #Europe #EU #Sanofi #Germany #Munich #Nuvaxovid #recipients #riskdifference #studyparticipants #systemicsymptoms #vaccines
https://www.europesays.com/france/21304/

Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic …

This article first appeared on GuruFocus. Q4 2025 Sales: EUR11.3 billion, 13.3% growth. Full-Year 2025 Sales: EUR43.6 billion,…
#France #FR #Europe #EU #Sanofi #BrianFoard #salesgrowth #ShareBuybackProgram
https://www.europesays.com/france/21265/

Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director

Sanofi Winthrop Industrie Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an …
#France #FR #Europe #EU #Sanofi #AnnualGeneralMeeting #ChiefExecutiveOfficer #ChristelHeydemann #ExecutiveCommittee #ExecutiveVicePresident #Heydemann #independentdirector #Jean-PaulKress #OrangeGroup #PatrickKron #SchneiderElectric
https://www.europesays.com/france/19913/

Drug Regulation and Innovation: How Sanofi Collaborates with the FDA

Once an expedited pathway is granted, the therapeutics dossier – a thorough collection of documents submitted to the…
#France #FR #Europe #EU #Sanofi #Approval #drugdevelopment #DrugSafety #Expedited #FDA #regulatory #review
https://www.europesays.com/france/19189/

https://www.europesays.com/be-fr/106716/ Des opportunités à saisir avec les actions du brasseur belge AB InBev et du groupe numérique Aubay, Lumibird dans les petits papiers des analystes de Stifel… Consultez La lettre des placements du 13 mai #ABInBev #actions #Alten #Axa #BE #BEFr #Belgique #Belgium #Bourse #Business #Économie #Economy #Eiffage #investissement #moncler #PEA #Rexel #roche #Sanofi #Vinci